The evolution and ongoing challenge of unproven cell-based interventions.

Area of Science:

• Regenerative Medicine
• Health Policy
• Biotechnology

Background:

• Unproven cell-based interventions (CBIs) emerged in the early 2000s.
• These therapies pose significant physical and financial risks to patients.
• They also impede the development of rigorous evidence for novel cell therapies.

Purpose of the Study:

• To examine the emergence and evolution of unproven CBIs.
• To analyze policy approaches to address the problem of unproven CBIs.
• To explore challenges in policy efforts and suggest future directions.

Main Methods:

• Review of the emergence and evolution of unproven CBIs over two decades.
• Analysis of various policy approaches pursued or proposed.
• Examination of challenges in policy implementation and effectiveness.

Main Results:

• Unproven CBIs have persisted as a policy challenge for over 20 years.
• Policy efforts have faced difficulties in effectively curbing unproven CBIs.
• The field's evolution presents ongoing challenges for regulation and patient safety.

Conclusions:

• Continued attention is needed for current and future unproven CBIs.
• Minimizing patient risk and promoting evidence-based cell therapies are critical.
• Addressing unproven CBIs is essential for the responsible advancement of regenerative medicine.